TrialBlood advances2023

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.

Loretta J Nastoupil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.